Prenetics Global Ltd.

Company Overview

The Prenetics Group, founded in 2014, markets genetic testing services for a range of applications including pharmacogenomics, nutrigenomics, cancer, and reproductive health.

In April 2018, Prenetics acquired DNAFit, giving it entry into the DTC market. DNAFit provided well genetics tests directly to consumers to help with diet, nutrition and fitness plans based on their genomic profiles.

Prenetics’ Onedna test is a screening service to provide customers with a comprehensive view and analysis of their genes together with actionable recommendations. The results may include insights into a person’s health status and risk for disease, optimal diet and nutrition, indications about how a patient may respond to various medications, and identification of the patient’s risk of common cancers.

In November 2018, Prenetics and Berry genomics agreed to form a consumer testing company to serve the Chinese market. The new company, Circle DNA, became operational in 2019. Two tests are marketed: Diet Fitness Pro 360 (a test kit for those who want to understand how their DNA affects their diet, nutrition and exercise profile) and Cancer DNA Test (a test kit for accessing clinically relevant variants in 35 genes associated with hereditary cancer risk).

In October 2019, Prenetics partnered with Hew Horizon Health covering the commercialization of New Horizon’s ColoClear colorectal cancer test in Hong Kong and other Asian markets. ColoClear is a stool-based DNA test designed to detect colon cancer in individuals of Asian descent, with 92% sensitivity demonstrated in clinical studies.

In July 2019, Prenetics formed a partnership with A.S. Watson Group, one of Asia’s largest personal care retailers, to sell its consumer DNA tests. Prenetics’ consumer DNA testing kit, Circle DNA, is now available for sale in Watson’s Hong Kong retail stores and is available online in Hong Kong, Singapore, Macau, Australia, New Zealand, the United Kingdom, United States, Canada, Thailand, and the Philippines.

In April 2020, Prenetics began collaborating with Prudential, CUHK (Chinese University Hong Kong) and others to launch Project Screen, a non-profit initiative aimed at improving accessibility to COVID-19 molecular testing in Hong Kong. The partnership made available to homes in Hong Kong the WHO-approved RT-PCR test for SARS-CoV-2, the virus that causes COVID-19, at no profit to the organizers.

In October 2020, Prenetics acquired Oxsed, a University of Oxford spinout that is developing and marketing a rapid test for SARS-CoV-2.

Prenetics’ consumer DNA tests use whole-exome sequencing, which provides 50 to 100 times more data than array-based tests.

In January 2023, Prenetics Global Ltd. made a notable announcement regarding its recent acquisition of a majority stake in ACT Genomics. The disclosure revealed that ACT Genomics had successfully obtained clearance from the U.S. Food and Drug Administration (FDA) for its comprehensive genomic profiling test for solid tumors, known as ACTOnco. This diagnostic tool is designed to assist healthcare professionals in making informed clinical management decisions for cancer patients with solid tumors, aligning with established professional guidelines. The achievement marked a significant milestone as ACT Genomics, now under the umbrella of Prenetics Global Ltd., became the first and only Asia-based company to secure FDA clearance for a comprehensive genomic profiling test.

Financial Highlights (FY 2024)

Company's Business Segments

• Prevention : This segment includes CircleDNA a consumer genetic testing.
• Diagnostics : This segment includes ACT Genomics a precision oncology.
• Consumer Health : This segment includes IM8 Health Supplements brand, Europaa sports distribution company.